Research Papers:

SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade

Rivki Cashman, Helit Cohen, Rotem Ben-Hamo, Alona Zilberberg and Sol Efroni _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:1071-1082. https://doi.org/10.18632/oncotarget.1783

Metrics: PDF 1823 views  |   HTML 2255 views  |   ?  


Rivki Cashman1, Helit Cohen1, Rotem Ben-Hamo1, Alona Zilberberg1 and Sol Efroni1

1 Faculty of Life Sciences, Bar Ilan University, Ramat-Gan, Israel


Sol Efroni, email:

Keywords: SENP5, Breast Cancer, SUMOylation, TGFBR1

Received: January 9, 2014 Accepted: February 16, 2014 Published: February 18, 2014


Identifying novel mechanisms, which are at the core of breast cancer biology, is of critical importance. Such mechanisms may explain response to treatment, reveal novel targets or drive detection assays.

To uncover such novel mechanisms, we used survival analysis on gene expression datasets encompassing 1363 patients. By iterating over the compendia of genes, we screened for their significance as prognosis biomarkers and identified SUMO-specific protease 5 (SENP5) to significantly stratify patients into two survival groups across five unrelated tested datasets. According to these findings, low expression of SENP5 is associated with good prognosis among breast cancer patients.

Following these findings, we analyzed SENP5 silencing and show it is followed by inhibition of anchorage-independence growth, proliferation, migration and invasion in breast cancer cell lines. We further show that these changes are conducted via regulation of TGFβRI levels. These data relate to recent reports about the SUMOylation of TGFβRI. Following TGFβRI changes in expression, we show that one of its target genes, MMP9, which plays a key role in degrading the extracellular matrix and contributes to TGFβ-induced invasion, is dramatically down regulated upon SENP5 silencing.

This is the first report represents SENP5-TGFβ-MMP9 cascade and its mechanistic involvement in breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1783